Almirall, S.A.'s latest marketcap:
As of 07/05/2025, Almirall, S.A.'s market capitalization has reached $2.72 B. According to our data, Almirall, S.A. is the 5107th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 2.72 B |
| Revenue (ttm) | 1.21 B |
| Net Income (ttm) | 28.67 M |
| Shares Out | 214.79 M |
| EPS (ttm) | 0.13 |
| Forward PE | 34.86 |
| Ex-Dividend Date | 05/15/2025 |
| Earnings Date | 07/25/2025 |
Almirall, S.A.'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | €2.72 B | 31.47% | 5107 |
| 12/31/2024 | €1.76 B | -0.35% | 6059 |
| 12/29/2023 | €1.76 B | 7.51% | 5698 |
| 12/30/2022 | €1.64 B | -19.23% | 5813 |
| 12/30/2021 | €2.03 B | 4.44% | 5603 |
| 12/31/2020 | €1.95 B | -23.89% | 4806 |
| 12/31/2019 | €2.56 B | 9.94% | 3626 |
| 12/31/2018 | €2.32 B | 60.96% | 3307 |
| 12/29/2017 | €1.44 B | -43.43% | 5028 |
| 12/30/2016 | €2.55 B | -20.77% | 3192 |
Company Profile
About Almirall, S.A.
Almirall, S.A. is a biopharmaceutical company specializing in skin health, operating across Spain, Europe, the Middle East, the United States, Asia, and Africa.
Product Portfolio
The company provides treatments for a wide range of skin conditions, including:
- Psoriasis
- Atopic dermatitis
- Acne
- Actinic keratosis
- Onychomycosis
- Androgenic alopecia
- Oncodermatology
- Orphan indications
Additionally, Almirall offers products for:
- Alimentary tract and metabolism
- Antiinfectives for systemic use
- Cardiovascular, musculoskeletal, nervous, and respiratory systems
- Dermatologicals
- Genito urinary system and sex hormones
- Immunostimulants
- Metabolism
- Systematic hormonal preparations
Partnerships & Research
Almirall has a multi-target partnership with Etherna to advance mRNA-based therapies for medical dermatology.
Company Background
Founded in 1943, the company was formerly known as Laboratorios Almirall, S.A. before rebranding to Almirall, S.A. in May 2009. Its headquarters are located in Barcelona, Spain.
Frequently Asked Questions
-
What is Almirall, S.A.'s (BME-ALM) current market cap?As of 07/05/2025, Almirall, S.A. (including the parent company, if applicable) has an estimated market capitalization of $2.72 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Almirall, S.A. (BME-ALM) rank globally by market cap?Almirall, S.A. global market capitalization ranking is approximately 5107 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.